Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023PRNewsWire • 06/21/23
Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate UpdatePRNewsWire • 06/05/23
Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic SclerosisPRNewsWire • 06/02/23
Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate UpdatePRNewsWire • 05/11/23
Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate UpdatePRNewsWire • 04/12/23
Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business UpdatePRNewsWire • 03/17/23
Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic SclerosisPRNewsWire • 02/21/23
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH PatientsPRNewsWire • 01/03/23
Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing CholangitisPRNewsWire • 12/21/22
Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & StrategyPRNewsWire • 11/30/22
Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 11/11/22
Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19PRNewsWire • 11/09/22
Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business UpdatePRNewsWire • 11/01/22
Chemomab Therapeutics Ltd. (CMMB) CEO Dale Pfost on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/12/22
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical CapabilitiesPRNewsWire • 08/12/22
Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 08/12/22